Last November, a 46-year-old strength coach named Greg in Scottsdale told his prescribing clinician he'd been running ipamorelin continuously for nine months. "I just never stopped because I felt great," he said. His IGF-1 had climbed to 347 ng/mL, well above the upper reference range for his age. His clinician pulled him off for eight weeks, retested, and the number settled back to 241. Greg's takeaway: "I thought cycling was optional. Turns out my body had something to say about that."
Most research-informed ipamorelin protocols use a cycled schedule, not continuous dosing. The most common pattern is 8 to 12 weeks on, followed by 4 weeks off. The rationale: reduce theoretical receptor desensitization, preserve responsiveness across multiple cycles, and keep cumulative exposure within a range that clinicians feel comfortable managing. Ipamorelin is not FDA-approved. It is a compounded research peptide dispensed by licensed pharmacies for individual patients. Individual results vary.
The Case For (and Against) Taking Breaks
Three arguments support cycling:
- The growth hormone secretagogue receptor (GHSR-1a) is a G-protein-coupled receptor, and like most GPCRs, it's theoretically subject to desensitization under sustained stimulation. Think of it like noise-canceling headphones that slowly stop noticing the drone of an airplane engine.
- Your body releases growth hormone in pulses, not a steady drip. Continuous dosing drifts away from that pulsatile pattern.
- Long-term human data on continuous ipamorelin use simply doesn't exist in any meaningful volume, so cycling is a bet on caution.
The counterargument is straightforward: no large randomized human trial has directly demonstrated desensitization with continuous ipamorelin dosing at compounded research doses. Some clinicians run patients on longer continuous stretches and report no issues. But the conservative default in compounded peptide practice remains cycling, and for good reason. When the data is thin, you hedge toward biology's own rhythms.
Four Common Cycling Patterns
12 Weeks On / 4 Weeks Off is the most frequently cited pattern in clinical-practice literature. Dose 200 to 300 mcg once or twice daily for twelve weeks, then pause completely for four. This gives a full benefit window with a manageable break. The downside is the commitment: you're looking at a four-month block before you can meaningfully assess one full cycle.
8 Weeks On / 4 Weeks Off shortens the feedback loop. Same dosing (200 to 300 mcg, once or twice daily), but you get to evaluate your response sooner. This is generally the better choice for a first cycle. You learn how your body responds without being locked in for three months.
5 Days On / 2 Days Off (Weekly Microcycle) skips the monthly structure entirely. Dose Monday through Friday, take weekends off, continue indefinitely. Some clinicians like this because it builds regular recovery into every week. The catch: the evidence base here is almost entirely anecdotal, and it's harder to compare outcomes against the more established monthly patterns.
12 Weeks On / 8 Weeks Off is the most conservative long-term approach. Maximum receptor recovery, smallest cumulative exposure. The obvious tradeoff: you're spending more time off than on.
Picking the Right Schedule
Here's the thing. There's no single correct protocol. But a practical decision tree works for most people:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →If it's your first cycle, go shorter. 8 on, 4 off. See what happens. If you respond well and want to continue, move to 12 on, 4 off for ongoing use. If cumulative exposure makes you or your clinician uneasy (say you've been running cycles for over a year), shift to 12 on, 8 off. If you train with seasonal goals, like a competitive CrossFit season or a bodybuilding prep, align the cycle with the training block.
The prescribing clinician should always direct the actual protocol.
What the Off-Period Actually Feels Like
Most people notice a gradual drift back toward their pre-cycle baseline during the off weeks. Sleep quality edges toward what it was before. Recovery between training sessions feels a little slower. This is normal and expected, not a sign that something went wrong.
The first two weeks off tend to feel the most noticeable. A mild subjective dip. By week three or four, most people stabilize and stop noticing a difference. Think of it less as withdrawal and more as your body re-establishing its own rhythm.
Restarting After a Break
When you come back after a standard off-cycle (three to six weeks), most clinicians don't bother with a full titration restart. Resume at the same dose you ended the prior cycle on, Day 1.
If you've been off longer than three months, a brief titration restart is reasonable. If you've been off longer than six months, treat it more or less like a new start.
Mid-Cycle Adjustments Worth Knowing
Not every cycle goes according to plan. A few common scenarios and how clinicians typically handle them:
If you feel minimal response by week four, try increasing frequency (once to twice daily) before bumping the per-dose amount. More frequent pulses often matter more than bigger pulses.
Mild water retention? Drop the per-dose amount by 50 to 100 mcg. If you're getting sleep disruption from a pre-bed dose, move it 30 to 60 minutes earlier. And if your response seems to fade during weeks 8 to 12, that's likely end-of-cycle attenuation, which is itself a signal to transition into your planned off-period rather than try to push through.
Stacking and Synchronization
When ipamorelin is stacked with CJC-1295 (with or without DAC), start and stop both peptides at the same time. Staggering them complicates your ability to assess what's actually working.
When stacking with non-GH peptides (GHK-Cu for skin, epithalon for sleep architecture), synchronization isn't necessary. Different mechanisms, different timelines. Run them independently.
Monitoring Across Multiple Cycles
For patients running ipamorelin across multiple years, periodic lab work keeps things from drifting into territory like Greg's. A reasonable monitoring schedule:
- IGF-1 at baseline, then every 6 to 12 months
- Fasting glucose and HbA1c at the same intervals
- TSH and free T4 annually
- An honest annual reassessment of clinical goals (are you still getting what you wanted, or just continuing out of habit?)
There's no published upper limit on the number of cycles. But "continuing indefinitely without a check-in" is a mistake, not a strategy.
When to Stop
Some situations call for discontinuation, not just an off-cycle:
- Active or recently diagnosed malignancy
- New uncontrolled diabetes
- New thyroid abnormality
- Persistent side effects that carry across multiple cycles
- You've reached your goal and don't need maintenance
The boring truth is that the last one applies more often than people admit. Sometimes you're done and the peptide has served its purpose.
Common Mistakes That Undermine the Whole Point
Running 12-plus months continuously without a break. Treating the off-period as a "half-dose" period (off means off, completely). Stopping mid-cycle on a whim without reaching the planned endpoint. Restarting multiple peptides at staggered intervals within the same stack, making it impossible to attribute results. And failing to track subjective response at all, which means you can't compare cycle to cycle and you're essentially flying blind.
FAQ
Do I really need to cycle ipamorelin?
Controlled-trial data on continuous ipamorelin use in humans is limited. Most clinicians cycle as a precaution. Some patients do run longer continuous protocols under clinical direction without reported problems, but the absence of reported problems isn't the same as evidence of safety.
What is the minimum off-period?
Most protocols call for three to four weeks minimum. Shorter off-periods exist in practice, but the rationale supporting them is thin.
Can I switch to a different peptide during the off-period?
If the off-period is meant to let the GH axis return to baseline, switching to another GH secretagogue defeats the purpose entirely. Switching to a non-GH peptide (like GHK-Cu) is a different story and generally fine.
Will my benefits come back after the off-period?
Most users report benefits returning within two to four weeks of restarting. The off-period doesn't erase body composition changes, particularly if you maintained your training and nutrition during the break.
What if I miss doses mid-cycle?
An occasional missed dose doesn't reset the cycle. But if you're missing more than two or three doses per week, you've effectively turned the cycle into an underdosed one. That's worth flagging with your prescribing clinician.
Related Reading
---
Disclaimer: Ipamorelin is not FDA-approved. It is a compounded research peptide dispensed by licensed pharmacies for individual patients under a valid prescription. This article is for educational purposes and does not constitute medical advice. Individual results vary. Always consult a licensed prescribing clinician before starting any compounded peptide protocol.
Citation: Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.